1-(3-aminobenzyl)-3-phenylurea | 515153-75-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(3-aminobenzyl)-3-phenylurea
• 英文别名: N-(3-aminobenzyl)-N'-phenylurea；1-[(3-aminophenyl)methyl]-3-phenylurea
• CAS: 515153-75-0
• 化学式: C₁₄H₁₅N₃O
• 分子量: 241.293
• InChiKey: QHCISTOINXYZTM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  67.2
• 氢给体数：
  3
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(3-aminobenzyl)-3-phenylurea 、 咪唑并[1,2-a]吡啶-3-甲酸 在 N-羟基-7-氮杂苯并三氮唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 16.0h， 生成 imidazo[1,2-a]pyridine-3-carboxylic acid {3-[(3-phenylureido)methyl]phenyl}amide
  参考文献：
  名称：

  Fragment-Based Discovery of Potent and Selective DDR1/2 Inhibitors

  摘要：

  The DDR1 and DDR2 receptor tyrosine kinases are activated by extracellular collagen and have been implicated in a number of human diseases including cancer. We performed a fragment-based screen against DDR1 and identified fragments that bound either at the hinge or in the back pocket associated with the DFG-out conformation of the kinase. Modeling based on crystal structures of potent kinase inhibitors facilitated the "back-to-front" design of potent DDR1/2 inhibitors that incorporated one of the DFG-out fragments. Further optimization led to low nanomolar, orally bioavailable inhibitors that were selective for DDR1 and DDR2. The inhibitors were shown to potently inhibit DDR2 activity in cells but in contrast to unselective inhibitors such as dasatinib, they did not inhibit proliferation of mutant DDR2 lung SCC cell lines.

  DOI：

  10.1021/acsmedchemlett.5b00143
• 作为产物：
  描述：

  3-氨基苄胺 、 异氰酸苯酯 以 二氯甲烷 为溶剂， 反应 16.0h， 以100%的产率得到1-(3-aminobenzyl)-3-phenylurea
  参考文献：
  名称：

  Fragment-Based Discovery of Potent and Selective DDR1/2 Inhibitors

  摘要：

  The DDR1 and DDR2 receptor tyrosine kinases are activated by extracellular collagen and have been implicated in a number of human diseases including cancer. We performed a fragment-based screen against DDR1 and identified fragments that bound either at the hinge or in the back pocket associated with the DFG-out conformation of the kinase. Modeling based on crystal structures of potent kinase inhibitors facilitated the "back-to-front" design of potent DDR1/2 inhibitors that incorporated one of the DFG-out fragments. Further optimization led to low nanomolar, orally bioavailable inhibitors that were selective for DDR1 and DDR2. The inhibitors were shown to potently inhibit DDR2 activity in cells but in contrast to unselective inhibitors such as dasatinib, they did not inhibit proliferation of mutant DDR2 lung SCC cell lines.

  DOI：

  10.1021/acsmedchemlett.5b00143

文献信息

• Palladium-Catalyzed Aerobic Oxidative Carbonylation of Amines Enables the Synthesis of Unsymmetrical N,N′-Disubstituted Ureas
  作者：Honglan Zeng、Hongyan Du、Wei Han、Xu Gong、Jie Zhang

  DOI：10.1055/a-1500-9673

  日期：2021.7

  A ligand-free palladium-catalyzed aerobic oxidative carbonylation of amines for the synthesis of ureas, particular unsymmetrically N,N′-disubstituted ureas, which cannot be accessed by any other palladium-catalyzed oxidative carbonylation of amines to date, is presented. An array of symmetrical and unsymmetrical ureas were straightforwardly synthesized by using inexpensive, readily available, stable

  提出了用于合成脲的无配体的钯催化的胺的好氧氧化羰基化反应，特别是不对称的N，N'-二取代的脲，迄今为止，其他任何钯催化的胺的氧化羰基化反应均无法获得。通过使用廉价，易于获得，稳定和安全的胺，在1个大气压下以良好或优异的收率直接合成了一系列对称和不对称的脲。这种新颖的方法采用氧气作为唯一氧化剂，为基于过渡金属的氧化剂系统提供了有吸引力的替代方法
• 2'-Methyl-5-(1,3,4-oxadiazol-2-yl)1,1'-biphenyl-4-carboxaide derivatives and their use as p38 kinase inhibitors
  申请人：——

  公开号：US20040266839A1

  公开（公告）日：2004-12-30

  Compounds of formula (I), wherein R 1 is a phenyl group which may be optionally substituted; R 2 is selected from hydrogen, C 1-6 alkyl and (CH 2 ) p —C 3-7 cycloalkyl; R 3 is the group: (Formula II), R 4 is selected from hydrogen and C 1-4 alkyl; U is selected from methyl and halogen; X and Y are each selected independently from hydrogen, methyl and halogen; m is selected from 0, 1, 2, 3 and 4, and may be optionally substituted with up to two groups selected independently from C 1-6 alkyl; n is selected from 0, 1 and 2; p is selected from 0, 1 and 2; or pharmaceutically acceptable salts or solvates thereof, and their use as pharmaceuticals, particularly as p38 kinase inhibitors. 1

  公式（I）的化合物，其中R1是苯基，可以选择性地被取代；R2选自氢、C1-6烷基和(CH2)p-C3-7环烷基；R3是基团：（公式II），R4选自氢和C1-4烷基；U选自甲基和卤素；X和Y各自独立地选自氢、甲基和卤素；m选自0、1、2、3和4，并且可以选择性地被最多两个独立选择自C1-6烷基的基团取代；n选自0、1和2；p选自0、1和2；或其药学上可接受的盐或溶剂，以及它们作为药物的用途，特别是作为p38激酶抑制剂。
• RHO KINASE INHIBITORS
  申请人：Dahmann Georg

  公开号：US20100041645A1

  公开（公告）日：2010-02-18

  Substituted amide and urea derivatives useful as inhibitors of Rho kinase are described, which inhibitors can be useful in the treatment of various disorders such as cardiovascular diseases, cancer, neurological diseases, renal diseases, bronchial asthma, erectile dysfunction and glaucoma.

  本文介绍了一种替代酰胺和脲衍生物，这些衍生物可用作Rho激酶的抑制剂，在治疗心血管疾病、癌症、神经系统疾病、肾脏疾病、支气管哮喘、勃起功能障碍和青光眼等各种疾病中有用。
• 2′-Methyl-5-(1,3,4-oxadiazol-2-yl)1, 1′-biphenyl-4-carboxaide derivatives and their use as p38 kinase
  申请人：Glaxo Group Limited

  公开号：US07384963B2

  公开（公告）日：2008-06-10

  Compounds of formula (I), wherein R1 is a phenyl group which may be optionally substituted; R2 is selected from hydrogen, C1-6 alkyl and (CH2)p—C3-7cycloalkyl; R3 is the group: (Formula II), R4 is selected from hydrogen and C1-4 alkyl; U is selected from methyl and halogen; X and Y are each selected independently from hydrogen, methyl and halogen; m is selected from 0, 1, 2, 3 and 4, and may be optionally substituted with up to two groups selected independently from C1-6 alkyl; n is selected from 0, 1 and 2; p is selected from 0, 1 and 2; or pharmaceutically acceptable salts or solvates thereof, and their use as pharmaceuticals, particularly as p38 kinase inhibitors

  化合物的公式（I），其中R1是苯基，可以选择性地被取代; R2选自氢，C1-6烷基和（CH2）p-C3-7环烷基; R3是基团：（公式II），R4选自氢和C1-4烷基; U选自甲基和卤素; X和Y各自独立地选自氢，甲基和卤素; m选自0、1、2、3和4，并可以选择性地用最多两个独立选择的C1-6烷基取代; n选自0、1和2; p选自0、1和2; 或其药学上可接受的盐或溶剂，以及它们作为药物的用途，特别是作为p38激酶抑制剂。
• SULFONAMIDE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF
  申请人：University of Tsukuba

  公开号：EP3309146A1

  公开（公告）日：2018-04-18

  The present invention aims to provide a novel low-molecular-weight compound exhibiting an orexin receptor agonist activity and expected to be useful as a prophylactic or therapeutic agent for narcolepsy and the like. The present invention provides a compound represented by the formula (I): wherein each symbol is as defined in the description, or a pharmaceutically acceptable acid addition salt thereof, which has an orexin receptor agonist activity, and an orexin receptor agonist containing the compound or a pharmaceutically acceptable acid addition salt thereof.

  本发明旨在提供一种新型低分子量化合物，该化合物具有奥曲肽受体激动剂活性，有望用作嗜睡症等的预防或治疗药物。本发明提供了一种由式（I）代表的化合物： 其中各符号如描述中所定义，或其药学上可接受的酸加成盐，具有奥曲肽受体激动剂活性，以及含有该化合物或其药学上可接受的酸加成盐的奥曲肽受体激动剂。